Dimitrios A. Chatzidimitriou

Prof. Dr. Dimitrios A. Chatzidimitriou

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
Olga TsachouridouOlga Tsachouridou
Olga Tsachouridou
AGAdamantini Georgiou
Adamantini Georgiou
SNSymeon Naoum
Symeon Naoum
DVDimitra Vasdeki
Dimitra Vasdeki
MPMaria Papagianni
Maria Papagianni
SMSymeon Metallidis
Symeon Metallidis
Introduction: Vaccination against various pathogens is recommended for HIV positive adults. There are not sufficient data either on vaccination coverage of HIV positive adults or the risk factors associated with poor adherence to routine vaccination. Patients-Methods: During the period 2004–2014 vaccination coverage of a group of HIV infected adults against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal influenza virus and pneumococcal disease was recorded. Vaccination coverage was separated into two chronological periods, before and after 2010, as 2010 marks the start of the economic crisis in Greece. Results: 1210 patients were included in our study. Vaccine coverage throughout the study for hepatitis B, hepatitis A, seasonal influenza and pneumococcal infection was 73.6%, 70.4%, 39% and 79%, respectively. The complete lack of insurance coverage was an independent factor of non-compliance in all proposed vaccines (vaccination against pneumococcal disease: OR: 0.82 95%CI: 0.49–1.35, vaccination against HBV: OR: 0.82, 95% CI: 0.45–1.49, vaccination against HAV OR: 0.54, 95%CI: 0.34–0.87, vaccination against influenza: OR: 1.27, 95% CI: 0.76–2.10). In addition, low educational level was associated with poor compliance to vaccination against pneumococcal disease, hepatitis A, hepatitis B, and influenza. Finally, the recommendation for vaccination after the onset of the economic crisis (2010) led to poor compliance to vaccination against HBV, HAV and pneumococcal disease, but not against influenza. Conclusions: In our study, vaccination coverage for vaccine-preventable diseases was found to be insufficient for HIV positive adults in Northern Greece. Also, low educational level, lack of insurance coverage and economic distress have contributed to poor vaccine compliance, leading to poor protection of the HIV positive population and decreased immune coverage in the community.

10 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
FCFani Chatzopoulou
Fani Chatzopoulou
KKKonstantinos A. Kyritsis
Konstantinos A. Kyritsis
CPChristos I. Papagiannopoulos
Christos I. Papagiannopoulos
Eleftheria GalatouEleftheria Galatou
Eleftheria Galatou
NMNikolaos Mittas
Nikolaos Mittas
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
MicroRNAs (miRNAs) create systems networks and gene-expression circuits through molecular signaling and cell interactions that contribute to health imbalance and the emergence of cardiovascular disorders (CVDs). Because the clinical phenotypes of CVD patients present a diversity in their pathophysiology and heterogeneity at the molecular level, it is essential to establish genomic signatures to delineate multifactorial correlations, and to unveil the variability seen in therapeutic intervention outcomes. The clinically validated miRNA biomarkers, along with the relevant SNPs identified, have to be suitably implemented in the clinical setting in order to enhance patient stratification capacity, to contribute to a better understanding of the underlying pathophysiological mechanisms, to guide the selection of innovative therapeutic schemes, and to identify innovative drugs and delivery systems. In this article, the miRNA–gene networks and the genomic signatures resulting from the SNPs will be analyzed as a method of highlighting specific gene-signaling circuits as sources of molecular knowledge which is relevant to CVDs. In concordance with this concept, and as a case study, the design of the clinical trial GESS (NCT03150680) is referenced. The latter is presented in a manner to provide a direction for the improvement of the implementation of pharmacogenomics and precision cardiovascular medicine trials.

3 October 2012 in Future Microbiology
Verified
Journal Article
Closed access
DCDimitrios A. Chatzidimitriou
Dimitrios A. Chatzidimitriou
DKDimitrios Kirmizis
Dimitrios Kirmizis
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
MARIA CHATZIDIMITRIOUMARIA CHATZIDIMITRIOU
MARIA CHATZIDIMITRIOU
NMNikolaos Malisiovas
Nikolaos Malisiovas
Atherosclerosis is a chronic inflammatory process accounting for increased cardiovascular and cerebrovascular morbidity and mortality. A wealth of recent data has implicated several infectious agents, mainly Chlamydophila pneumoniae, Helicobacter pylori, CMV and periodontal pathogens, in atherosclerosis. Thus, we sought to comprehensively review the available data on the topic, exploring in particular the pathogenetic mechanisms, and discuss anticipated future directions.

Verified
Journal Article
Open access
PDF file
IMIoulia Mavrikou
Ioulia Mavrikou
DCDimitrios A. Chatzidimitriou
Dimitrios A. Chatzidimitriou
Lemonia SkouraLemonia Skoura
Lemonia Skoura
ENEmmanouil Nikolousis
Emmanouil Nikolousis
ISIoanna Sakellari
Ioanna Sakellari
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) detected in the liver has been considered a severe complication of hematopoietic stem cell transplantation (HSCT). SOS/VOD is characterized by hepatomegaly, right upper quadrant pain, jaundice, and ascites. The severe forms of the disease may result in multi-organ dysfunction (MOD) with a high mortality rate (>80%). The development of SOS/VOD can be rapid and unpredictable. Therefore, early identification and severity assessment is crucial in facilitating prompt diagnosis and timely treatment. Effective treatment and potential prophylaxis with defibrotide highlight the need for characterizing a sub-group of patients at high risk for SOS/VOD. Moreover, antibodies that are conjugated with calicheamicin, gemtuzumab, and inotuzumab ozogamicin, have led to renewed interest in this syndrome. Evaluation and management of serious adverse events associated with gemtuzumab and inotuzumab ozogamicin are recommended. We review hepatic-, transplant- and patient-related risk factors, criteria for diagnosis and grading classification, and SOS/VOD potential biomarkers. Furthermore, we examine pathogenesis, clinical presentation, diagnostic criteria, risk factors, prophylaxis, and treatment of SOS/VOD occurring post HSCT. Moreover, we aim to provide an up-to-date summary of molecular advances in the diagnosis and management of SOS/VOD. We performed a comprehensive review of the literature and examined the recently available data, mostly using the PubMed and Medline search engines for original articles published over the last decade. In the era of precision medicine, our review provides up-to-date knowledge of genetic or sera markers for SOS/VOD with the goal of identifying a subset of high-risk patients.

19 January 2010 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
DCDimitrios A. Chatzidimitriou
Dimitrios A. Chatzidimitriou
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
ISIoanna Sakellari
Ioanna Sakellari
EDE. Diza
E. Diza

19 October 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Evangelia KostakiEvangelia Kostaki
Evangelia Kostaki
MGMaria Gova
Maria Gova
GAGeorgios Adamis
Georgios Adamis
GXGeorgios Xylomenos
Georgios Xylomenos
MCMaria Chini
Maria Chini
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
Our aim was to investigate the dispersal patterns and parameters associated with local molecular transmission clusters (MTCs) of subtypes A1 and B in Greece (predominant HIV-1 subtypes). The analysis focused on 1751 (28.4%) and 2575 (41.8%) sequences of subtype A1 and B, respectively. Identification of MTCs was based on phylogenetic analysis. The analyses identified 38 MTCs including 2–1518 subtype A1 sequences and 168 MTCs in the range of 2–218 subtype B sequences. The proportion of sequences within MTCs was 93.8% (1642/1751) and 77.0% (1982/2575) for subtype A1 and B, respectively. Transmissions within MTCs for subtype A1 were associated with risk group (Men having Sex with Men vs. heterosexuals, OR = 5.34, p < 0.001) and Greek origin (Greek vs. non-Greek origin, OR = 6.05, p < 0.001) and for subtype B, they were associated with Greek origin (Greek vs. non-Greek origin, OR = 1.57, p = 0.019), younger age (OR = 0.96, p < 0.001), and more recent sampling (time period: 2011–2015 vs. 1999–2005, OR = 3.83, p < 0.001). Our findings about the patterns of across and within country dispersal as well as the parameters associated with transmission within MTCs provide a framework for the application of the study of molecular clusters for HIV prevention.